Corbus Pharmaceuticals Holdings (CRBP) Cash from Financing Activities (2013 - 2025)

Corbus Pharmaceuticals Holdings' Cash from Financing Activities history runs 13 years deep, the most recent figure standing at $2.9 million for Q3 2025.

• In Q3 2025, Cash from Financing Activities fell 88.62% year-over-year to $2.9 million; the TTM figure through Sep 2025 stood at $2.8 million (down 98.28% YoY), while the FY2024 annual figure was $166.6 million, up 6004.93% from the prior year.
• Cash from Financing Activities was $2.9 million for Q3 2025 at Corbus Pharmaceuticals Holdings, up from -$13000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $106.6 million in Q1 2024 to a low of -$1.9 million in Q4 2023.
• Historically, Cash from Financing Activities has averaged $13.3 million across 5 years, with a median of -$13000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 912.98% in 2023, then jumped 194042.14% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at $767938.0 in 2021, then slumped by 69.49% to $234322.0 in 2022, then plunged by 912.98% to -$1.9 million in 2023, then soared by 99.32% to -$13000.0 in 2024, then surged by 22030.77% to $2.9 million in 2025.
• The last three Cash from Financing Activities figures came in at $2.9 million (Q3 2025), -$13000.0 (Q4 2024), and $25.0 million (Q3 2024), per Business Quant data.